Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

11C-Glutamine and 18F-FSPG PET Imaging in Diagnosing Patients with Metastatic Colorectal Cancer

The clinical trial studies how well 11C-glutamine and 18F-FSPG positron emission tomography (PET) imaging works in detecting tumors in patients with metastatic colorectal cancer compared to standard imaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scanning.
Colon, Rectal
Not Available
Not Available
Manning, Henry
Vanderbilt University
Glutamine PET Imaging of Colorectal Cancer


18 Years
Inclusion Criteria:

Pathologically or cytologically confirmed diagnosis of metastatic (stage IV) RAS wildtype CRC

Eligible for anti-EGFR monoclonal antibody (mAb) therapy as standard-of-care (SOC), either as a single agent or in combination with approved SOC therapies or investigational agents as part of Institutional Review Board (IRB)-approved clinical trials

Archived tissue from the CRC primary tumor in sufficient amounts to allow ribonucleic acid (RNA)-sequencing (seq) gene analysis; specimen from metastatic sites are not required but highly preferred

Documented results from (or scheduled to undergo) CT or MRI of the chest, abdomen and pelvis as a SOC procedure within 28 days of baseline investigational 11C-Gln PET/CT and 18F-FSPG PET/CT

Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1

At least one lesion > 2 cm in diameter and thus will be measurable according to PET Response Criteria in Solid Tumors (PERCIST) v1.0 to avoid PET partial volume effects

Ability to provide written informed consent in accordance with institutional policies

Exclusion Criteria:

Any other current or previous malignancy within the past 5 years

Previous EGFR-directed therapy

Body weight >= 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed

Pregnant or lactating females

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: